S&P 500   3,139.82 (-2.67%)
DOW   27,180.11 (-2.79%)
QQQ   216.58 (-2.17%)
AAPL   291.45 (-2.26%)
FB   199.03 (-0.84%)
MSFT   168.89 (-1.17%)
GOOGL   1,395.01 (-1.75%)
AMZN   1,973.95 (-1.76%)
NVDA   261.40 (-4.35%)
BABA   205.51 (-0.32%)
MU   52.18 (-5.14%)
GE   11.30 (-4.72%)
TSLA   803.24 (-3.66%)
AMD   47.70 (-2.89%)
ACB   1.51 (-2.58%)
F   7.29 (-3.83%)
NFLX   361.31 (-2.00%)
DIS   128.79 (-3.17%)
S&P 500   3,139.82 (-2.67%)
DOW   27,180.11 (-2.79%)
QQQ   216.58 (-2.17%)
AAPL   291.45 (-2.26%)
FB   199.03 (-0.84%)
MSFT   168.89 (-1.17%)
GOOGL   1,395.01 (-1.75%)
AMZN   1,973.95 (-1.76%)
NVDA   261.40 (-4.35%)
BABA   205.51 (-0.32%)
MU   52.18 (-5.14%)
GE   11.30 (-4.72%)
TSLA   803.24 (-3.66%)
AMD   47.70 (-2.89%)
ACB   1.51 (-2.58%)
F   7.29 (-3.83%)
NFLX   361.31 (-2.00%)
DIS   128.79 (-3.17%)
S&P 500   3,139.82 (-2.67%)
DOW   27,180.11 (-2.79%)
QQQ   216.58 (-2.17%)
AAPL   291.45 (-2.26%)
FB   199.03 (-0.84%)
MSFT   168.89 (-1.17%)
GOOGL   1,395.01 (-1.75%)
AMZN   1,973.95 (-1.76%)
NVDA   261.40 (-4.35%)
BABA   205.51 (-0.32%)
MU   52.18 (-5.14%)
GE   11.30 (-4.72%)
TSLA   803.24 (-3.66%)
AMD   47.70 (-2.89%)
ACB   1.51 (-2.58%)
F   7.29 (-3.83%)
NFLX   361.31 (-2.00%)
DIS   128.79 (-3.17%)
S&P 500   3,139.82 (-2.67%)
DOW   27,180.11 (-2.79%)
QQQ   216.58 (-2.17%)
AAPL   291.45 (-2.26%)
FB   199.03 (-0.84%)
MSFT   168.89 (-1.17%)
GOOGL   1,395.01 (-1.75%)
AMZN   1,973.95 (-1.76%)
NVDA   261.40 (-4.35%)
BABA   205.51 (-0.32%)
MU   52.18 (-5.14%)
GE   11.30 (-4.72%)
TSLA   803.24 (-3.66%)
AMD   47.70 (-2.89%)
ACB   1.51 (-2.58%)
F   7.29 (-3.83%)
NFLX   361.31 (-2.00%)
DIS   128.79 (-3.17%)
Log in

NYSEAMERICAN:AMPE - Ampio Pharmaceuticals Stock Price, Forecast & News

$0.62
-0.02 (-3.13 %)
(As of 02/25/2020 02:25 PM ET)
Today's Range
$0.61
Now: $0.62
$0.65
50-Day Range N/A
52-Week Range
$0.26
Now: $0.62
$1.31
Volume29,750 shs
Average Volume1.26 million shs
Market Capitalization$98.36 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSEAMERICAN:AMPE
CUSIP03209T10
Phone+1-720-4376500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees22
Market Cap$98.36 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive AMPE News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.


Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Frequently Asked Questions

What is Ampio Pharmaceuticals' stock symbol?

Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."

When is Ampio Pharmaceuticals' next earnings date?

Ampio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Ampio Pharmaceuticals.

What price target have analysts set for AMPE?

1 analysts have issued 12-month target prices for Ampio Pharmaceuticals' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Ampio Pharmaceuticals' share price to reach $4.00 in the next year. This suggests a possible upside of 545.3% from the stock's current price. View Analyst Price Targets for Ampio Pharmaceuticals.

What is the consensus analysts' recommendation for Ampio Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ampio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ampio Pharmaceuticals.

Has Ampio Pharmaceuticals been receiving favorable news coverage?

Press coverage about AMPE stock has trended very negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Ampio Pharmaceuticals earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Ampio Pharmaceuticals.

Who are some of Ampio Pharmaceuticals' key competitors?

What other stocks do shareholders of Ampio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ampio Pharmaceuticals investors own include Trevena (TRVN), Cerus (CERS), NovaBay Pharmaceuticals (NBY), Protalix Biotherapeutics (PLX), Athersys (ATHX), AVEO Pharmaceuticals (AVEO), NVIDIA (NVDA), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA) and Catalyst Pharmaceuticals (CPRX).

Who are Ampio Pharmaceuticals' key executives?

Ampio Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael E. Macaluso, Founder, Chairman & CEO (Age 67)
  • Mr. Thomas E. Chilcott III, CFO, Treasurer & Sec. (Age 51)
  • Ms. Holli Cherevka, Chief Operating Officer (Age 36)

Who are Ampio Pharmaceuticals' major shareholders?

Ampio Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include CVA Family Office LLC (0.74%), Valeo Financial Advisors LLC (0.34%), Cypress Capital Management LLC WY (0.17%), Brighton Jones LLC (0.10%), Renaissance Technologies LLC (0.09%) and Traynor Capital Management Inc. (0.06%). View Institutional Ownership Trends for Ampio Pharmaceuticals.

Which major investors are selling Ampio Pharmaceuticals stock?

AMPE stock was sold by a variety of institutional investors in the last quarter, including Cypress Capital Management LLC WY and Renaissance Technologies LLC. View Insider Buying and Selling for Ampio Pharmaceuticals.

Which major investors are buying Ampio Pharmaceuticals stock?

AMPE stock was purchased by a variety of institutional investors in the last quarter, including CVA Family Office LLC, Valeo Financial Advisors LLC, Brighton Jones LLC and Traynor Capital Management Inc.. View Insider Buying and Selling for Ampio Pharmaceuticals.

How do I buy shares of Ampio Pharmaceuticals?

Shares of AMPE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ampio Pharmaceuticals' stock price today?

One share of AMPE stock can currently be purchased for approximately $0.62.

How big of a company is Ampio Pharmaceuticals?

Ampio Pharmaceuticals has a market capitalization of $98.34 million. Ampio Pharmaceuticals employs 22 workers across the globe.View Additional Information About Ampio Pharmaceuticals.

What is Ampio Pharmaceuticals' official website?

The official website for Ampio Pharmaceuticals is http://ampiopharma.com/.

How can I contact Ampio Pharmaceuticals?

Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The specialty pharmaceutical company can be reached via phone at +1-720-4376500.


MarketBeat Community Rating for Ampio Pharmaceuticals (NYSEAMERICAN AMPE)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Ampio Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel